Skip to content
← Holders

Tri Locum Partners LP

What Tri Locum Partners LP reported holding on Form 13F for the quarter ended Sep 30, 2026.

CIK 1826434 · Filed Nov 16, 2026

Positions
18
Reported value
$506.1M
Opened
3
Closed
4
Other managers included
0

Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR

Quarters on file

  1. Sep 30, 2025$435.1M
    18 positions
  2. Dec 31, 2025$770.1M
    15 positions
  3. Mar 31, 2026$712.5M
    17 positions
  4. Jun 30, 2026$813.2M
    19 positions
  5. Sep 30, 2026$506.1M
    18 positions
SecuritySharesChangeValueOf portfolio
VRTXVertex Pharmaceuticals Inc
132.9K−34.1%$69.5M13.7%
LLYEli Lilly & Co
51K−33.3%$59M11.7%
TEVATeva Pharmaceutical Industries Ltd
1.2M+63.9%$48.5M9.6%
AMRXAmneal Pharmaceuticals, Inc.
2.3MNew$46.9M9.3%
DXCMDexCom Inc
489.4K−40.4%$42.2M8.3%
JAZZJazz Pharmaceuticals plc
160.3K−27.7%$37.1M7.3%
ARGXArgenx SE
30.4K−26.9%$29.1M5.8%
ASNDAscendis Pharma A/S
118.4K−54.2%$27M5.3%
AXSMAxsome Therapeutics, Inc.
143.3K−34.6%$26.4M5.2%
JNJJohnson & Johnson
73.6K−82.7%$19.5M3.8%
ELVNEnliven Therapeutics, Inc.
410.2K−52.7%$18.8M3.7%
UTHRUnited Therapeutics Corp
33K−29.8%$17.9M3.5%
MDGLMadrigal Pharmaceuticals, Inc.
33.7K−50.7%$17M3.4%
CELCCelcuity Inc.
202.6KNew$16.1M3.2%
DNTHDianthus Therapeutics, Inc.
177.2K+46.8%$15.6M3.1%
RVMDRevolution Medicines, Inc.
40K−73.6%$8.2M1.6%
DFTXDefinium Therapeutics, Inc.
144.4K−11.4%$5.5M1.1%
VRDNViridian Therapeutics, Inc.
90.1KNew$1.9M0.4%